Posted by Michael Wonder on 27 Dec 2024
Alnylam Canada signs letter of intent from pan-Canadian Pharmaceutical Alliance for the public reimbursement of Amvuttra for the treatment of hereditary transthyretin-mediated amyloidosis in adults
18 October 2024 - One step closer to achieving public reimbursement of Amvuttra for hereditary transthyretin-mediated amyloidosis. patients in Canada
Alnylam Canada is pleased to announce that it has signed a letter of intent with the pan-Canadian Pharmaceutical Alliance for the public reimbursement of Amvuttra (vutrisiran injection), an RNAi therapeutic administered by quarterly subcutaneous injection, for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin-mediated amyloidosis.
